Biocept's Liquid Biopsy CTC Testing for Breast Cancer to Be Featured in Poster Presentation at the 2019 San Antonio Breast Cancer Symposium®
Poster and session details:
Title: Clinical Data in Over 1,500 Patients Across All Stages of Breast Cancer with Target Selector Circulating Tumor Cell Technology
Authors:
Session Title: Poster Session 4
Session Date and Time:
"Our CTC-based liquid biopsy testing offers physicians the ability to assess metastatic disease burden and informative biomarkers to aid clinical decision making in patients with breast cancer," said
"We are very pleased to showcase this large data set at SABCS demonstrating the ability of our Target Selector™ assays to help physicians better understand treatment options for their patients with breast cancer," said
About the 2019 San Antonio Breast Cancer Symposium®
SABCS's mission is to provide state-of-the-art information on breast cancer research. From a one-day regional conference, the Symposium has grown to a five-day program attended by a broad international audience of academic and private researchers and physicians from over 90 countries. SABCS aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer.
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including, without limitation, statements as to our ability to improve the management, diagnosis and treatment of cancer, and the ability of our tests to provide clinically actionable information to oncologist and their patients, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Contact:
LHA Investor Relations
Jcain@lhai.com
310-691-7100
View original content to download multimedia:http://www.prnewswire.com/news-releases/biocepts-liquid-biopsy-ctc-testing-for-breast-cancer-to-be-featured-in-poster-presentation-at-the-2019-san-antonio-breast-cancer-symposium-300967937.html
SOURCE